Searchable abstracts of presentations at key conferences in endocrinology

ea0011p482 | Endocrine tumours and neoplasia | ECE2006

48 h appears as sufficient duration of fasting in the diagnosis of insulinoma – a single centre experience with 23 cases

Quinkler M , Strehlow F , Biering H , Pirlich M , Gerl H , Strasburger CJ , Ventz M

Insulinoma causes fasting hypoglycemia due to inappropriate insulin secretion. The diagnosis of insulinoma is based on Whipple’s triad (1. symptoms precipitated by fasting with 2. associated blood sugars of 50 mg/dl or less and 3. relief of symptoms by glucose administration) during a supervised 72 h fasting test. After introducing reliable assays for measurement of insulin and proinsulin, there is an ongoing debate whether a 48 h fasting test is sufficient for diagnosis ...

ea0011p511 | Endocrine tumours and neoplasia | ECE2006

The latest safety and efficacy data of patients treated with Pegvisomant

Schreiber I , Forssmann K , Buchfelder M , Droste M , Mann K , Saller B , Strasburger CJ

The German Acrostudy is at present the largest database on acromegalics (n=184) treated with pegvisomant (Somavert®). 91% pts underwent pituitary surgery, 45% received radiation therapy, and previous medical therapy included dopamine agonists (56%), octreotide (90%) and/or lanreotide (10%). Common concomitant diseases at baseline were hypertension (47.0%), diabetes mellitus (31.7%), and gallstone disease (25.6%). Efficacy analysis was performed in 134 pt...

ea0011p626 | Neuroendocrinology and behaviour | ECE2006

The influence of a GH receptor antagonist (GHRA) on the relationship between GH and IGF-I in adults with severe growth hormone deficiency (AGHD)

Pokrajac A , Berg CA , Bidlingmaier M , Strasburger CJ , Shalet SM , Trainer PJ

Approximately 50% of patients with severe AGHD (defined by the international consensus criteria, peak GH <3 ng/ml) have a normal age- and gender-related IGF-I. It remains unclear whether in these individuals IGF-I is GH-dependent.We performed a double-blind, randomised, placebo-controlled, cross-over study on the effect of pegvisomant (20 mg daily for 14 days) on the relationship between GH and IGF-I in 3 age-, gender- and BMI-matched cohorts (Norms:...

ea0011p627 | Neuroendocrinology and behaviour | ECE2006

Can adults with severe growth hormone deficiency (AsGHD) and a low IGF-I be distinguished from those with a normal IGF-I?

Berg CA , Pokrajac A , Bidlingmaier M , Strasburger CJ , Mann K , Shalet SM , Trainer PJ

Approximately 50% of patients with severe AGHD (defined by the international consensus criteria, peak GH <3 ng/ml) have a normal age- and gender-related IGF-I. It remains unclear whether in these individuals IGF-I is GH-dependent. We performed a double-blind, randomised, placebo-controlled, cross-over study on the effect of pegvisomant (20 mg daily for 14 days) on the relationship between GH and IGF-I in 3 age-, gender- and BMI-matched cohorts (Norms: 5 GHD patients with n...

ea0003oc32 | Metabolism | BES2002

Regulation of leptin receptor cleavage

Maamra M , Bidlingmaier M , Postel-Vinay M , Wu Z , Strasburger C , Ross R

The leptin receptor (ObR) exists in multiple isoforms. In humans, there is no mRNA encoding soluble receptor (LBP). We investigated the hypothesis that human LBP can be generated by proteolytic cleavage of membrane anchored leptin receptors (ObRb and ObRa). LBP, of similar size to that previously detected in human serum, was detected in medium of cells transfected with ObRa by HPLC, Immunofluorometric assay, and Ligand mediated immunofluorometric assay, but not by ELISA. The L...

ea0012s4biog | Society for Endocrinology European Medal Lecture | SFE2006

Society for Endocrinology European Medal Lecture

Costagliola S

C Strasburger, Charite Campus Mitte, Berlin, Germany AbstractSince 2003 Christian J Strasburger has been Division Chief and Professor of Clinical Endocrinology at the Department of Medicine at Charité-Universitätsmedizin Berlin, Germany. He graduated from the Medizinische Universität Lübeck, Germany and trained in internal medicine and endocrinology at the Universities of Lübeck and Munich. He ...

ea0014oc10.2 | Obesity &amp; metabolism | ECE2007

11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) mRNA expression in liver of patients with non-alcoholic steatohepatitis

Konopelska Sarah , Kienitz Tina , Pirlich Matthias , Bauditz Jürgen , Stewart Paul M. , Lochs Herbert , Strasburger Christian J. , Quinkler Marcus

Background: Non-alcoholic fatty liver disease (NAFLD) is recognized as common liver disorder that represents the hepatic manifestation of the metabolic syndrome including visceral obesity, type 2 diabetes, insulin resistance and hyperlipidemia. Non-alcoholic steatohepatitis (NASH) is the progressive form of liver injury with the risk for progressive fibrosis, cirrhosis and end-stage liver disease. The pathophysiology that leads to NAFLD and NASH is not well understood. We hypo...

ea0013p171 | Diabetes, metabolism and cardiovascular | SFEBES2007

Abdominal obesity is associated with a decreased hepatic mRNA expression of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) in patients with non-alcoholic steatohepatitis (NASH)

Konopelska Sarah , Kienitz Tina , Pirlich Matthias , Bauditz Juergen , Stewart Paul M , Hughes Beverly , Lochs Herbert , Strasburger Christian J , Quinkler Marcus

Background: Non-alcoholic fatty liver disease (NAFLD) is recognized as common liver disorder that represents the hepatic manifestation of the metabolic syndrome including visceral obesity, type 2 diabetes, insulin resistance and hyperlipidemia. Non-alcoholic steatohepatitis (NASH) is the progressive form of liver injury with the risk for progressive fibrosis, cirrhosis and end-stage liver disease. The pathophysiology that leads to NAFLD and NASH is not well understood. We hypo...

ea0094p85 | Neuroendocrinology and Pituitary | SFEBES2023

Development of an optimal imaging pathway for management of somatotroph tumors in acromegaly

Haberbosch Linus , Macfarlane James , Koulouri Olympia , Gillett Dan , Spranger Joachim , Mai Knut , Cheow Heok , Jones Jonathan , Strasburger Christian , Gurnell Mark

Background: Acromegaly is associated with significant excess morbidity and mortality. Surgery and radiotherapy (including radiosurgery) aim to reduce the burden of growth hormone excess while preserving normal pituitary function, but their effective deployment is dependent on high quality imaging that allows accurate localization of site(s) of active de novo or residual/recurrent disease. Despite the existence of several comprehensive guidelines on the managem...

ea0063p236 | Pituitary and Neuroendocrinology 1 | ECE2019

Serum aryl hydrocarbon receptor-interacting protein (AIP) levels are independent of serum GH levels both at baseline and in dynamic tests of GH stimulation and suppression

Stojanovic Marko , Wu Zida , Stiles Craig , Miljic Dragana , Soldatovic Ivan , Pekic Sandra , Doknic Mirjana , Petakov Milan , Popovic Vera , Strasburger Christian , Korbonits Marta

Background and aim: Aryl hydrocarbon receptor-interacting protein (AIP) is evolutionary conserved and widely distributed throughout organism. Broad interest for AIP comes from involvement of loss-of-function AIP mutations in pituitary adenoma pathogenesis. The role of AIP in normal pituitary function is largely unknown. AIP is co-localized with GH in somatotroph secretory vesicles. Serum AIP protein was proteomically identified. We aimed at investigating whether AIP and GH are...